Medication use by athletes during the Athens 2004 Paralympic Games

British Journal of Sports Medicine

Volumn 43, Issue 13, 2009, Pages 1062-1066

  Tsitsimpikou, C ^a,b   Jamurtas, A ^a,c   Fitch, K ^d   Papalexis, P ^b   Tsarouhas, K ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b Athens 2004 Organising Committee for the Olympic Games   (Greece)

^c INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ATHLETES; DIETARY SUPPLEMENTS; DISABLED PERSONS; DOPING IN SPORTS; DRUG THERAPY; GREECE; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 73349129667     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsm.2009.062521     Document Type: Article

References (32)

1. Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sport Med 2003;13:33-40.
2. Huang SH, Johnson K, Pipe AL. The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games. Clin J Sport Med 2006;16:27-33.
3. Tsitsimpikou C, Tsiokanos A, Tsarouhas K, et al. Medication use by athletes at the Athens 2004 Summer Olympic Games. Clin J Sport Med 2009;19:33-8.
4. World Anti-Doping Agency. International standard list of prohibited substances and methods. Montreal: World Anti-Doping Agency, 2004.
5. World Anti-Doping Agency. International standard for testing 3.0. Montreal: World Anti-Doping Agency, 2003.
6. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate:cardiac protective action through caritine-lowering effect. Trends Cardiovasc Med 2002;12:275-9.
7. Sjakste N, Gutcaits A, Kalvinsh I. Mildronate: an anti-ischemic drug for neurological indications. CNS Drug Rev 2005;11:151-68.
8. World Anti-Doping Agency. Independent observers report, Olympic Summer Games 2004. Montreal: World Anti-Doping Agency, 2004.
9. Ferrara MS, Davis RW. Injuries to elite wheelchair athletes. Paraplegia 1990;28:335-41.
10. Nilsen R, Nygaard P, Bjorholt PG. Complications that may occur in those with spinal cord injuries who participate in sport. Paraplegia 1985;23:152-8.
11. Iezzi A, Ferri C, Mezzetti A, et al. COX-2: friend or foe? Curr Pharm Des 2007;13:1715-21.
12. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
13. Ferrara MS, Buckley WE, McCann BC, et al. The injury experience of the competitive athlete with a disability: prevention implications. Med Sci Sports Exerc 1992;24:184-8.
14. Webborn N, Willick S, Reeser JC. Injuries among disabled athletes during the 2002 Winter Paralympic Games. Med Sci Sports Exerc 2006;38:811-15.
15. Meyers MC, Brown BR, Bloom JA. Fast pitch softball injuries. Sport Med 2001;31:61-73.
16. Thuyne WV, Delbeke FT. Declared use of medication in sports. Clin J Sport Med 2008;18:143-7.
17. Klenck C, Gebke K. Practical management: common medical problems in disabled athletes. Clin J Sport Med 2007;17:55-60.
18. Bauman WA, Spungen AM, Raza M, et al. Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt Sinai J Med 1992;59:163-8.
19. Dearwater SR, LaPorte RE, Robertson RJ, et al. Activity in the spinal cord-injured patient: an epidemiologic analysis of metabolic parameters. Med Sci Sports Exerc 1986;18:541-4.
20. Filho JA, Salvetti XM, de Mello MT, et al. Coronary risk in a cohort of Paralympic athletes. Br J Sports Med 2006;40:918-22.
21. Mojtahedi MC, Valentine RJ, Arngrimsson SA, et al. The association between regional body composition and metabolic outcomes in athletes with spinal cord injury. Spinal Cord 2008;46:192-7.
22. Wilt TJ, Carlson KF, Goldish GD, et al. Carbohydrate and lipid disorders and relevant considerations in persons with spinal cord injury. Evid Rep Technol Assess 2008;163:1-95.
23. 2 agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006;117:767-73.
24. Fitch KD, Sue-Chu M, Anderson SD, et al. Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. J Allergy Clin Immunol 2008;122:254-60.
25. Bhambhani Y. Physiology of wheelchair racing in athletes with spinal cord injury. Sports Med 2002;32:23-51.
26. Price MJ. Thermoregulation during exercise in individuals with spinal cord injuries. Sport Med 2006;36:863-79.
27. Rastmanesh R, Taleban FA, Kimiagar M, et al. Nutritional knowledge and attitudes in athletes with physical disabilities. J Athl Train 2007;42:99-105.
28. Perret C, Mueller G, Knecht H. Influence of creatine supplementation on 800 m wheelchair performance: a pilot study. Spinal Cord 2006;44:275-9.
29. Schmid A, Schmidt-Trucksass A, et al. Catecholamines response of high performance wheelchair athletes at rest and during exercise with autonomic dysreflexia. Int J Sports Med 2001;22:2-7.
30. Yekutiel M, Brooks ME, Ohry A. The prevalence of hypertension ischemic heart disease and diabetes in traumatic spinal cord injured patients and amputees. Paraplegia 1989;27:58-62.
31. Nelson RR, Gobel FL, Jorgensen CR, et al. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation 1974;50:1179-89.
32. Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc 2004;36:533-53.